Filing Flows

Filing Flows › Companies › iBio › Cash flow

iBio cash flow, quarter by quarter

Latest: Q4 FY26 · from the cash-flow statements filed with the SEC

Free cash flow−$6.2M in Q4 FY26

Operating cash flow−$6.2M
Capital spending−$19K
Free cash flow−$6.2M

Analysis

In Q4 FY26, iBio generated −$6.2M of operating cash flow and spent $19K on capital projects, leaving free cash flow of −$6.2M. That is $1.6M less than in Q4 FY25 (−$4.6M).

Operating cash flow was −$6.2M against net income of −$10.6M. The largest differences: accrued liabilities +$2.8M, payables +$1.4M, stock-based pay +$420K.

Free cash flow

iBio: free cash flow by quarteriBio: free cash flow by quarter−$3.7MQ1 FY25−$3.9MQ2 FY25−$3.1MQ3 FY25−$4.6MQ4 FY25−$5.7MQ1 FY26−$5.8MQ2 FY26−$6.1MQ3 FY26−$6.2MQ4 FY26
Operating cash flow less capital spending.
iBio: operating cash flow against capital spendingiBio: operating cash flow against capital spendingOperating cash flowCapital spending−$3.7M$0Q1 FY25−$3.9M$1KQ2 FY25−$3.1M$14KQ3 FY25−$4.6M$1KQ4 FY25−$5.7M$32KQ1 FY26−$5.2M$516KQ2 FY26−$6.1M$11KQ3 FY26−$6.2M$19KQ4 FY26
Latest (Q4 FY26): Operating cash flow −$6.2M, Capital spending $19K.

Capital allocation, year by year

iBio: where the cash came from (up) and went (down), by fiscal yeariBio: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingAcquisitionsFY22: Operating cash flow −$37.5MFY22: Net borrowing −$5.8MFY22: Shares issued $77KFY22: Capital spending −$7.3M$77KFY22FY23: Operating cash flow −$30.4MFY23: Net borrowing −$9.5MFY23: Shares issued $11.5MFY23: Asset sales $2.6MFY23: Capital spending −$5.7MFY23: Acquisitions −$692K$14.1MFY23FY24: Operating cash flow −$18.6MFY24: Net borrowing −$686KFY24: Shares issued $25.5MFY24: Asset sales $116KFY24: Capital spending −$210K$25.6MFY24FY25: Operating cash flow −$15.3MFY25: Net borrowing −$517KFY25: Shares issued $3.7MFY25: Capital spending −$16K$3.7MFY25FY26: Operating cash flow −$23.2MFY26: Net borrowing −$710KFY26: Shares issued $3.5MFY26: Capital spending −$578K$3.5MFY26
Over these 5 years operating cash flow totalled −$125M; the largest uses were operating cash flow ($125M) and net borrowing ($17.3M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$88.0M
Debtnone
Net cash$88.0M
Cash runway3.5 years

iBio is burning cash: its operations consume cash, a free cash flow of −$25.0M a year at the current rate against $88.0M of cash and investments: a runway of about 3.5 years before any new financing.

Where the cash came from and went

iBio: sources (+) and uses (−) of cash, Q4 FY26iBio: sources (+) and uses (−) of cash, Q4 FY26Other financing$19.4MCash drawn (+) / kept (−)−$8.8MOperating cash flow−$6.2MOther investing−$4.4MCapital spending−$19K

From profit to cash

iBio: net income to operating cash flow, Q4 FY26iBio: net income to operating cash flow, Q4 FY26Net income−$10.6MDepreciation & amortization$152KStock-based pay$420KPayables$1.4MAccrued liabilities$2.8MOperating cash flow−$6.2M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q4 FY26−$6.2M−$19K——−$8.8M−$6.2M
Q3 FY26−$6.1M−$11K—$3.3M−$19.0M−$6.1M
Q2 FY26−$5.2M−$516K−$597K—−$561K−$5.8M
Q1 FY26−$5.7M−$32K−$8K$219K−$19.5M−$5.7M
Q4 FY25−$4.6M−$1K−$136K$2.4M−$3.6M−$4.6M
Q3 FY25−$3.1M−$14K−$131K$1.2M$2.1M−$3.1M
Q2 FY25−$3.9M−$1K−$127K—$4.0M−$3.9M
Q1 FY25−$3.7M—−$123K$4K$3.2M−$3.7M

iBio: income statement and cash flow

iBio, Q1 FY26: revenue $100K. The chart follows the revenue to costs, profit and cash.

iBio: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.